ArticleOphthalmology science2026
Choroidal Changes after Intravitreal Aflibercept, Faricimab, Brolucizumab, and High-Dose Aflibercept in Treatment-Naïve Neovascular Age-Related Macular Degeneration.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare choroidal structural changes after a loading phase of different anti-VEGF agents in treatment-naïve neovascular age-related macular degeneration (nAMD). Design: Retrospective, monocentric, observational cohort study. Subjects: Fifty-six eyes of 56 treatment-naïve patients with nAMD. Methods Intervention or Testing: Patients received 3 consecutive monthly intravitreal injections of aflibercept 2 mg, aflibercept 8 mg, brolucizumab, or faricimab. Multimodal imaging was performed at baseline and at 3 months using swept-source OCT. Central choroidal thickness (CCT) and choroidal vascularity index (CVI) were quantified. Changes from baseline were analyzed within and between treatment groups, with adjustment for age. Main Outcome Measures: Change in CCT and CVI after the loading phase. Results: All treatment groups demonstrated a significant reduction in CCT at 3 months (all Conclusions: Anti-VEGF therapy induces significant choroidal thinning in treatment-naïve nAMD during the loading phase. However, different agents demonstrate distinct choroidal compartmental effects. These findings suggest drug-specific patterns of choroidal remodeling, potentially influenced by molecular and pharmacologic properties, warranting further prospective evaluation to determine their clinical implications. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.